CELG: Message Board for Celgene Corporation | Forum profile

  Journal of Clinical Oncology , Vol 27, No 34 (December 1), 2009: pp. 5676-5677 2009 American Society of Clinical Oncology.   EDITORIALS   Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines   Jes?s F. San Miguel   Servicio de Hematolog?a. Hospital Universitario de Salamanca, Centro de Investigaci?n del C?ncer Instituto de Biologia Molecular y Celular del Cancer/CSIC, Universidad de...

If you go to the very last Institutional Holdings page for Celgene as of 9-30-09, at nasdaq.com , you will see that TCW Group, Inc. reduced its third quarter Celgene holdings to zero (0) shares, from 1,553,530 shares at the end of the second quarter. According to my calculations, this put it in third place as a Celgene "net seller" (i.e. net reduction in shares):   Janus Capital...

Signing off for the holiday. Lots to be grateful for ... From the country we live in ... To those at risk protecting us ... To family ... To football ... To having enough to merit following the market ... All the best.

This practice of taking everything off the board and not adding even a heavily discounted value for pipeline into the target price has got to stop.  Heaven forbid if you put a target price out there that may have so real connection to the existing and pipeline value, you'd have to be considerably higher than the current price and we can't have that. Problem seems to be that these firms have been so snake bit in the last...

CELG’s MM-015 Revlimid study a key focus The American Society of Hematology meeting will take place on Dec 5-8. We expect the MM-015 Phase 3 study of Revlimid in front-line multiple myeloma to be the key presentation for CELG. Although there has been investor controversy heading into this data presentation, we continue to expect positive results based on our statistical analysis (published Nov 9). We look for progression free...

  Guess the bear market rally wasnt over Sept 1. "Bear Rally" - what a joke. And the pompous attitude about it is annoying.   Wait for that next down 150+ Dow day for reasonable to return.   Bear Market Rally. He He _____________________________   Original Message (# 138852) by reasonable_risk on 9/1/2009 11:04:48 AM ot: is bear rally over? some think so ... prechter goes 100% short positioned for...

another demo of imids=immunomodulatory=good! msg 140912

  Celgene gains two exclusive worldwide licenses for major new class of drug targets June 7, 2001 Celgene Corporation (Warren, NJ) announced today that it has significantly expanded its intellectual property estate and its portfolio of novel drug targets through exclusive worldwide license agreements with three leading research institutions—New York University School of Medicine, the Research Foundation of the State...